Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Paulzen

Showing results (51-60 of 92) with videos related to

Pageof 10
Sort By:
Psychoneuroendocrinology|July 25, 2016
Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesisMichael Paulzen, Ekkehard Haen, Benedikt Stegmann, et al.
British Journal of Clinical Pharmacology|July 6, 2024
Discovering interactions in polypharmacy: Impact of metamizole on the metabolism of quetiapineFabian Watermeyer, Arnim Johannes Gaebler, Irene Neuner, et al.
Pharmacopsychiatry|August 9, 2020
Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring SampleGeorgios Schoretsanitis, Ekkehard Haen, Andreas Conca, et al.
Pharmacopsychiatry|December 8, 2020
Treatment Goals for Patients with Schizophrenia - A Narrative Review of Physician and Patient PerspectivesGerhard Gründer, Philipp Bauknecht, Stefan Klingberg, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 30, 2019
Pharmacokinetic correlates of venlafaxine: associated adverse reactionsGeorgios Schoretsanitis, Ekkehard Haen, Christoph Hiemke, et al.
Expert Review of Clinical Pharmacology|October 3, 2024
Pharmacokinetic interaction of quetiapine and lamotrigine - victim and perpetrator?Florian Gilleßen, Arnim Johannes Gaebler, Ekkehard Haen, et al.
International Clinical Psychopharmacology|May 17, 2019
Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramineChristoph Kowalewski, Ekkehard Haen, Christoph Hiemke, et al.
European Archives of Psychiatry and Clinical Neuroscience|April 6, 2021
Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) databaseGeorgios Schoretsanitis, Ekkehard Haen, Daria Piacentino, et al.
Journal of Psychopharmacology (Oxford, England)|February 6, 2021
Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesisMaxim Kuzin, Ekkehard Haen, Christoph Hiemke, et al.
Expert Review of Clinical Pharmacology|December 17, 2021
Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitateGeorgios Schoretsanitis, Ekkehard Haen, Daria Piacentino, et al.
Pageof 10

Showing results (51-60 of 92) with videos related to

Sort By:
Pageof 10
Psychoneuroendocrinology|July 25, 2016
Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesisMichael Paulzen, Ekkehard Haen, Benedikt Stegmann, et al.
British Journal of Clinical Pharmacology|July 6, 2024
Discovering interactions in polypharmacy: Impact of metamizole on the metabolism of quetiapineFabian Watermeyer, Arnim Johannes Gaebler, Irene Neuner, et al.
Pharmacopsychiatry|August 9, 2020
Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring SampleGeorgios Schoretsanitis, Ekkehard Haen, Andreas Conca, et al.
Pharmacopsychiatry|December 8, 2020
Treatment Goals for Patients with Schizophrenia - A Narrative Review of Physician and Patient PerspectivesGerhard Gründer, Philipp Bauknecht, Stefan Klingberg, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 30, 2019
Pharmacokinetic correlates of venlafaxine: associated adverse reactionsGeorgios Schoretsanitis, Ekkehard Haen, Christoph Hiemke, et al.
Expert Review of Clinical Pharmacology|October 3, 2024
Pharmacokinetic interaction of quetiapine and lamotrigine - victim and perpetrator?Florian Gilleßen, Arnim Johannes Gaebler, Ekkehard Haen, et al.
International Clinical Psychopharmacology|May 17, 2019
Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramineChristoph Kowalewski, Ekkehard Haen, Christoph Hiemke, et al.
European Archives of Psychiatry and Clinical Neuroscience|April 6, 2021
Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) databaseGeorgios Schoretsanitis, Ekkehard Haen, Daria Piacentino, et al.
Journal of Psychopharmacology (Oxford, England)|February 6, 2021
Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesisMaxim Kuzin, Ekkehard Haen, Christoph Hiemke, et al.
Expert Review of Clinical Pharmacology|December 17, 2021
Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitateGeorgios Schoretsanitis, Ekkehard Haen, Daria Piacentino, et al.
Pageof 10